EBMT 2022 | Advantages of primary NK cells for the treatment of patients with hematological malignancies
Tobias Bexte
• 16 Mar 2022
Tobias Bexte, University Hospital Frankfurt, Goethe University, Frankfurt, Germany, outlines the benefits of using primary natural killer (NK) cells to treat patients with hematological malignancies. Allogeneic gene-modified NK cells have a high cytotoxic capacity without MHC-specific receptor engagement and with a lower rate of side effects such as graft-versus-host disease (GvHD), cytokine release syndrome (CRS) or neurotoxicity than T-cells. In addition, NK cells can be manufactured as an off-the-shelf therapy. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
